Drug Profile
Oncamex
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Antoxis
- Class Flavonoids; Small molecules
- Mechanism of Action Free radical modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Cancer; Ovarian cancer
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Breast cancer in United Kingdom (unspecified route) (Antoxis pipeline, September 2023)
- 05 Sep 2023 Discontinued for Ovarian cancer in United Kingdom (unspecified route) (Antoxis pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for research development in Ovarian-cancer in United Kingdom